The Efficiency of the Central Venous Catheter Care Protocol

Sponsor
Saglik Bilimleri Universitesi Gulhane Tip Fakultesi (Other)
Overall Status
Recruiting
CT.gov ID
NCT05705895
Collaborator
(none)
60
1
2
23
2.6

Study Details

Study Description

Brief Summary

The study aims to evaluate the effectiveness of a central venous catheter (CVC) care protocol, which was created using current guidelines, research results, and expert opinions, on developing CVC-related bloodstream infection in patients with hematopoietic stem cell transplantation (HSCT) until discharge.

Condition or Disease Intervention/Treatment Phase
  • Procedure: CENTRAL VENOUS CATHETER CARE PROTOCOL
N/A

Detailed Description

Hematopoietic stem cell transplantation (HSCT) is one of the important treatment approaches that prolongs survival in patients with hematological malignancies, immunodeficiency and some solid tumors. Despite advances in the treatment process, reasons such as recurrence of the underlying disease, organ toxicities and infectious complications adversely affect treatment success. Reasons such as high-dose chemotherapy, frequent blood sampling, stem cell reinfusion, and total parenteral nutrition applied to HSCT patients increase the need for central venous catheter insertion. Although these tools are often necessary and useful in the bone marrow transplantation process, they also bring mechanical, embolic, and infectious complications.

Central venous catheters (CVC) are one of the main applications of modern clinical treatment. Reasons such as high-dose chemotherapy, frequent blood sampling, stem cell reinfusion, and total parenteral nutrition applied to HSCT patients increase the need for central venous catheter insertion. Although these tools are often necessary and valuable in the bone marrow transplantation process, they also bring mechanical, embolic, and infectious complications. The study aims to evaluate the effectiveness of a central venous catheter (CVC) care protocol, created using current guidelines, research results, and expert opinions, on developing CVC-related bloodstream infection in patients with hematopoietic stem cell transplantation (HSCT) until discharge.

This research is a pretest-posttest quasi-experimental clinical study. It is conducted with 60 patients between January 2022 and December 2023. The data is collected with Patient Information Form and Daily Patient Evaluation Chart. No application will be made to 30 patients in the control group, and catheter care will be provided to the patients of the intervention group in line with the CVC Care Protocol created by the researchers.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Masking Description:
Patients and care providers know which group they are in, but the outcome assessor does not.
Primary Purpose:
Supportive Care
Official Title:
Evaluation of the Efficiency of the Central Venous Catheter Care Protocol for Patients With Hematopoietic Stem Cell Transplantation
Actual Study Start Date :
Jan 1, 2022
Anticipated Primary Completion Date :
Jul 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention Group

Catheter care is provided in line with the CVC care protocol developed by the researcher.

Procedure: CENTRAL VENOUS CATHETER CARE PROTOCOL
Catheter care is provided in line with the CVC care protocol developed by the researcher: For subsequent catheter care, a transparent sterile catheter cover impregnated with 2% chlorhexidine gluconate will be used. The entry point of the catheter will be wiped with a disposable sterile skin cleaning applicator containing 2% Chlorhexidine Gluconate and 70% Isopropyl Alcohol, which will be provided by the researchers, and wait for it to dry. Vein valve/needleless connector will be used. Effective manual disinfection of needle-free connectors (hubs) will be ensured before each intervention. Needle-free connectors will be replaced every 96 hours at the latest. If necessary, the catheter lumen will be washed with a disposable, positive-pressure sterile washing system containing 10 ccs 0.9% sodium chloride to be provided by the investigators. Pulsatile "give stop give stop" technique will be used in the washing process.

No Intervention: Control Group

No intervention will be made to the patients in the control group, and catheter care will be provided in line with the clinical routine.

Outcome Measures

Primary Outcome Measures

  1. Patient Descriptive Information Form [Baseline]

    It was developed by the researchers by examining the literature; It contains information about the socio-demographic characteristics of the patients such as age, gender, marital status, educational status, and the planned chemotherapy protocol, previous treatments, and medical conditions such as chronic diseases. There are 8 questions in the first part of the form, which includes socio-demographic characteristics, and 12 questions in the second part, which includes information on medical status..

  2. Daily Patient Evaluation Chart [During the procedure]

    It was developed by researchers by examining the literature; patients' vital signs (recording of signs of infection such as hypotension, tachycardia, high fever), height-weight measurement results, daily central venous catheter insertion site control results (evaluation findings such as exudate, swelling, redness, discharge, etc.) and routine clinical procedures from patients every day. This is the chart in which the results of whole blood, CRP, Procalcitonin, sedimentation count values and hemoculture routinely taken at every fever, urine culture and catheter tip culture taken during discharge will be recorded. It also includes the control of the protocol implementation steps.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Being hospitalized by the Medical Oncology Clinic at in a training and research hospital to become an Autologous HSCT,

  • The patient has an 8F-size, two-lumen temporary CVC,

  • Over 18 years of age

  • There is no communication problem,

  • Agreeing to participate in the research voluntarily after being informed about the study,

Exclusion Criteria:
  • Using a vascular access method other than an 8F size two-lumen temporary CVC in the patient,

  • Refusal to participate in the research voluntarily after being informed about the study,

  • Identification of a different focus of infection in the patient.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Health Science University Gülhane Training and Research Hospital Ankara Turkey

Sponsors and Collaborators

  • Saglik Bilimleri Universitesi Gulhane Tip Fakultesi

Investigators

  • Principal Investigator: Canan PORUCU, MsN, RN, Saglik Bilimleri Universitesi

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Canan Yaranoglu, Nurse, MsN, RN, Principle Investigator, Saglik Bilimleri Universitesi Gulhane Tip Fakultesi
ClinicalTrials.gov Identifier:
NCT05705895
Other Study ID Numbers:
  • 2021/51
First Posted:
Jan 31, 2023
Last Update Posted:
Jan 31, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Canan Yaranoglu, Nurse, MsN, RN, Principle Investigator, Saglik Bilimleri Universitesi Gulhane Tip Fakultesi

Study Results

No Results Posted as of Jan 31, 2023